Laurus Labs Limited (NSE:LAURUSLABS)
625.65
-19.85 (-3.08%)
Apr 25, 2025, 3:30 PM IST
Laurus Labs Revenue
In the fiscal year ending March 31, 2025, Laurus Labs had annual revenue of 55.54B INR with 10.18% growth. Laurus Labs had revenue of 17.20B in the quarter ending March 31, 2025, with 19.49% growth.
Revenue
55.54B
Revenue Growth
+10.18%
P/S Ratio
5.99
Revenue / Employee
9.37M
Employees
6,007
Market Cap
337.38B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 55.54B | 5.13B | 10.18% |
Mar 31, 2024 | 50.41B | -10.00B | -16.55% |
Mar 31, 2023 | 60.41B | 11.05B | 22.39% |
Mar 31, 2022 | 49.36B | 1.22B | 2.54% |
Mar 31, 2021 | 48.14B | 19.82B | 69.99% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Cipla | 267.20B |
Mankind Pharma | 116.41B |
Apollo Hospitals Enterprise | 211.46B |
Zydus Lifesciences | 222.47B |
Aurobindo Pharma | 309.22B |
Alkem Laboratories | 127.57B |
Laurus Labs News
- 1 day ago - Laurus Labs Q4 Results: Revenue up 19.4% to Rs 1,720 crore, Net profit surges 210% YoY - Business Upturn
- 2 days ago - Stocks hitting 52-week highs today, April 23: Laurus Labs, UPL, Bharti Hexacom, HDFC Bank and more - Business Upturn
- 3 days ago - Stocks hitting 52-week highs today, April 22: HDFC Bank, Laurus Labs, Bharti Hexacom, Eicher Motors and more - Business Upturn
- 10 days ago - Laurus Labs receives EIR from USFDA for API manufacturing facility (Unit-4) at Atchutapuram - Business Upturn
- 2 months ago - Stocks hitting 52-week high today, February 5: UPL, Laurus Labs, Bajaj Finance, JK Cement and more - Business Upturn
- 3 months ago - Laurus Labs stock jumps 5% after US grants emergency humanitarian waiver for HIV treatment - Business Upturn
- 3 months ago - Laurus Labs shares tumble amid concerns over US foreign aid pause impacting AIDS relief funding. - The Times of India
- 3 months ago - Laurus Labs Ltd (BOM:540222) Q3 2025 Earnings Call Highlights: Strong CDMO Growth Amid ARV ... - GuruFocus